Provided by Tiger Fintech (Singapore) Pte. Ltd.

Titan Pharmaceuticals

4.08
0.0000
Volume:10.72K
Turnover:42.37K
Market Cap:5.43M
PE:-0.89
High:4.20
Open:3.94
Low:3.84
Close:4.08
52wk High:6.43
52wk Low:3.03
Shares:1.33M
Float Shares:723.50K
Volume Ratio:0.44
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6038
EPS(LYR):-5.2347
ROE:-82.72%
ROA:-44.08%
PB:1.95
PE(LYR):-0.78

Loading ...

Jan 27, 2021

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Jan 25, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 22, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 21, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 19, 2021

Major Issues Report

8-K - Current report
Jan 08, 2021

Major Issues Report

8-K - Current report
Jan 07, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 31, 2020

Major Issues Report

8-K - Current report
Dec 17, 2020

Major Issues Report

8-K - Current report
Dec 14, 2020

Correspondence

CORRESP [Cover] - Correspondence
Dec 08, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Dec 03, 2020

Major Issues Report

8-K - Current report
Dec 01, 2020

Major Issues Report

8-K - Current report
Nov 16, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 09, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 02, 2020

Major Issues Report

8-K - Current report
Oct 28, 2020

Major Issues Report

8-K - Current report
Oct 27, 2020

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Oct 26, 2020

Correspondence

CORRESP [Cover] - Correspondence
Oct 26, 2020

Correspondence

CORRESP [Cover] - Correspondence